PULM
Pulmatrix, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.36
+0.00%Year over year
Reported trailing growth
- Revenue
- -100.0%
- EBITDA
- +49.2%
- EBIT
- +48.6%
- EPS
- +49.1%
- Free cash flow
- +51.2%
- Operating cash flow
- +51.2%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -100.0%
- EBITDA
- +26.7%
- EBIT
- +47.1%
- Net income
- +46.0%
- EPS
- +46.2%
- Free cash flow
- +51.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026